Company
Portfolio Data
Back to Company Search231 SHEEP LLC
Address
160 W VALLEY BLVD STE BSAN GABRIEL, CA, 91776-3765
USA
UEI: KL5CHAX1LK64
Number of Employees: 7
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
SBIR/STTR Involvement
Year of first award: 2022
2
Phase I Awards
1
Phase II Awards
50%
Conversion Rate
$351,925
Phase I Dollars
$749,929
Phase II Dollars
$1,101,854
Total Awarded
Awards
Ocuelar: Revolutionizing Glaucoma Management in Medically Underserved Communities
Amount: $301,941 Topic: NIA
TBD
Tagged as:
SBIR
Phase I
2024
HHS
NIH
Ocuelar - Remote Eye Drop Medication Adherence Solution
Amount: $749,929 Topic: AF212-CSO1
Photorefractive keratectomy (PRK) surgery is a type of refractive laser eye surgery used to treat nearsightedness, farsightedness, and astigmatism by reshaping the cornea. PRK surgeries are very popular among active-duty DAF personnel as they enable Airmen to safely and quickly continue performing their duties and meet vision requirements without the need of glasses or contact lenses, which can impair performance and affect mission success. After a refractive surgery, which is also frequently performed in conjunction with cataract removal surgeries, patients are required to use eyedrop medications for up to 8 weeks to prevent infection and inflammation. However, medication non-compliance can cause postoperative complications including keratitis and uveitis, which add to patient care costs, lower quality of life, and can prevent DAF personnel from returning to their duties. In response, 231 Sheep has developed the Ocuelar platform, composed of: the Ocuelar SmartCap, a battery-free capsule that attaches to standard eyedrop bottles, monitoring patients’ eyedrop medication usage; the Ocuelar Patient App, a smartphone application that displays the data collected from the SmartCap and provides patients with analytics, feedback, and motivation to improve medication adherence; and Ocuelar Admin, a cloud platform for physicians, caregivers, and relatives to monitor patient adherence to medication.
Tagged as:
SBIR
Phase II
2022
DOW
USAF
Remote Medication Adherence solution for glaucoma patients
Amount: $49,984 Topic: AF212-CSO1
Glaucoma, a disease that damages your eye's optic nerve, affects more than 2.7 million individuals aged 40 or older in the US. The disease is the leading cause of blindness for veterans over 60 years old, mostly prevalent in veterans that suffer from PTSD
Tagged as:
SBIR
Phase I
2022
DOW
USAF